You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Responsible Drinking: Internet-based, Interactive Computer Tailored Intervention

    SBC: Pro-Change Behavior Systems Inc            Topic: NIAAA

    DESCRIPTION (provided by applicant): Excessive alcohol use is associated with a range of serious and costly health, social, and economic consequences at the individual and societal level. This program of research serves as a venue by which to produce and test an innovative, science-based, and cost-effective means to intervene in a private, convenient, and individualized way with employed adults wh ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  2. Computerized Stage-Matched Intervention for Juvenile Offenders

    SBC: Pro-Change Behavior Systems Inc            Topic: NIDA

    DESCRIPTION (provided by applicant): Juvenile crime imposes enormous costs on victims, on society, and on juvenile offenders themselves. However, research assessing the efficacy of interventions for young offenders show, on average, only small effects on recidivism, substance abuse, and other behavioral outcomes. A major problem with existing interventions is that they tend to neglect individual d ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  3. EpiVax Phase II SBIR: Preclinical studies of Tregitope Delivery and Mechanism of

    SBC: EPIVAX, INC.            Topic: NIDDK

    DESCRIPTION (provided by applicant): The goal of this Phase II project is to advance the development of novel tolerance-inducing peptides (Tregitopes) to prevent and/or treat Type 1 diabetes (T1D) by optimizing the clinical delivery vehicle and treatment protocol, and by identifying correlates of efficacy in preparation for Phase 1 clinical trials. More than 13,000 children in the U.S. are diagnos ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  4. Thin Diamond for Time-of-Flight Detectors

    SBC: Applied Diamond, Inc.            Topic: 35b

    Detectors and radiation monitors for future high energy and nuclear physics experiments must be able to withstand radiation environments several orders of magnitude harsher than those of any current device. At present, most radiation detectors are based on silicon technology, however, the practical radiation hardness limit of silicon falls far short of requirements in future high ener ...

    SBIR Phase I 2012 Department of Energy
  5. Novel Membrane Systems for Olefin/Paraffin Separation

    SBC: COMPACT MEMBRANE SYSTEMS, INC.            Topic: 18a

    Ethylene and propylene are the primary feedstocks for the manufacture of polyethylene and polypropylene, respectively. These olefins represent a major component of the polymer manufacturing cost. Consequently, there is significant economic benefit in minimizing losses of unreacted olefin from the process. Some olefin loss is a result of the need to remove paraffin from the polymerization reactor ...

    SBIR Phase I 2012 Department of Energy
  6. Diamond Refractive Focusing Optics

    SBC: Delaware Diamond Knives, Inc            Topic: 16a

    Synchrotron-based science has had a great scientific impact and will continue to have great impact going forward. In spite of the large investment in the 3rd generation light sources, most beam lines do not preserve the sources phase profile or brightness all the way to the sample. For these high brightness light sources, errors are almost completely due to distortion in the front-end optics cau ...

    SBIR Phase I 2012 Department of Energy
  7. Novel Tetravalent Vaccines for Dengue Virus

    SBC: ALTRAVAX, INC            Topic: NIAID

    DESCRIPTION (provided by applicant): Dengue virus infection is an emerging disease and an expanding global health problem. More than one-third of the world's population is at risk for transmission in tropical and subtropical areas and vaccines are an urgent public health priority. Although dengue rarely occurs in the continental United States, it is endemic in Puerto Rico, and in many popular ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  8. Germline-Specific Immunogens for the Induction of Neutralizing Antibodies to HIV-

    SBC: ALTRAVAX, INC            Topic: NIAID

    DESCRIPTION (provided by applicant): Vaccines are urgently needed to slow the spread of the HIV/AIDS epidemic, and immunogens that can induce neutralizing antibodies remain an important goal of vaccine research. An increasing number of human monoclonal antibodies (mAbs) have been isolated in recent years from individuals who show remarkably broad and potent neutralizing responses. Coupled with pas ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  9. Novel Therapeutic Vaccines for Chronic HBV

    SBC: ALTRAVAX, INC            Topic: NIAID

    DESCRIPTION (provided by applicant): Hepatitis B virus (HBV) is a noncytopathic, hepatotropic DNA virus that results in a self-limited acute infection in a majority of otherwise healthy individuals but can also cause chronic infection, particularly in newborns infected by vertical transmission. Chronic hepatitis B infection is a significant global health issue directly affecting 350 million people ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  10. Inducing Tolerance to Enzyme Replacement Therapy for Pompe Disease

    SBC: EPIVAX, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Inducing Tolerance to Enzyme Replacement Therapy for Pompe Disease Pompe disease is a lysosomal storage disorder caused by defects in the enzyme acid alpha-glucosidase (GAA) that leads to glycogen accumulation affectingheart and skeletal muscle. Enzyme-replacement therapy with recombinant human (rh)GAA saves the lives of children with Pompe disease. The prognos ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government